Brett Abrahams, Ph.D.

Position: Board Member

Dr. Abrahams is a geneticist turned drug hunter building early-stage neuro-focused startups. He led R&D activities at Magnolia Neurosciences, a Series A funded company developing small molecule therapeutics for neurodegenerative disorders, since its formation in 2018. He joined Magnolia from Ovid Therapeutics (NASDAQ: OVID) where he was Senior Director and Head, Pre-Clinical Biology. Before this, Dr. Abrahams was full-time faculty at the Albert Einstein College of Medicine, where he retains an adjunct appointment. His research, published in numerous high impact journals including Cell, New England Journal of Medicine, Nature, and Science Translational Medicine, has been cited more than 10,000 times.